Patent ID: 11938132
Assignee: ASTELLAS PHARMA INC.
Field: Pharmaceuticals (Chemistry)
Classification: CPC A | IPC A

Claim 2:
3. The method according to claim 1, wherein:
6-ethyl-3-(13-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl{amino)-5-(tetrahydro-2H-pyran-4-ylamino)pyrazine-2-carboxamide hemifumarate is combined with the at least one pharmaceutical additive to produce the mixture; and
a proportion of crystals of 6-ethyl-3-(13-methoxy-4-[4-(4-methylpiperazin -1-yl)piperidin-1-yl]phenyl}amino)-5-(tetrahydro-2H-pyran-4-ylamino)pyrazine-2-carboxamide hemifumarate is 62% to 98% with respect to a total amount of 6-ethyl-3-(13-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenylIamino)-5-(tetrahydro-2H-pyran-4-ylamino)pyrazine-2-carboxamide hemifumarate in the pharmaceutical composition, as determined by the near-infrared spectroscopy.